Takeda Pharmaceutical Company (C), The Future of Takeda

Takeda Pharmaceutical Company (C), The Future of Takeda

By
Chris Beaumont, Asaka Itoh, Hiromichi Kimura, Robert Kneller, Charles O'Reilly III
2012|Case No.OB83(C)

In addition to acquiring Millennium Pharmaceuticals in 2008 and Amgen Japan in 2009, Takeda implemented a major reorganization of its global organization. President Yasuchika Hasegawa reorganized Takeda’s business in the U.S. and aggressively expanded its global business. For the first time in Takeda’s history, Hasegawa appointed several non-Japanese to executive positions and moved away from a Japanese-centric governance system. Hasegawa felt confident that Takeda was becoming a global company and moving towards his vision of innovation, cultural transformation, and growth. Also see OB83(A), Takeda Pharmaceutical Company (A): Becoming a Global Company and OB83(B), Takeda Pharmaceutical Company (B): The Millennium Acquisition.

This material is available for download by current Stanford GSB students, faculty, and staff, as well as Stanford GSB alumni. For inquiries, contact the Case Writing Office.

Available for Purchase